DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Intepirdine
Intepirdine
Upcoming Market Catalysts in Q4 2017
The 1,3,5-Triazine Derivatives As Innovative Chemical Family of 5-HT6 Serotonin Receptor Agents with Therapeutic Perspectives for Cognitive Impairment
Drug Candidates in Clinical Trials for Alzheimer's Disease
2017 Medicines in Development for Alzheimer's Disease
UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
G-Protein-Coupled Receptors in CNS: a Potential Therapeutic Target for Intervention in Neurodegenerative Disorders and Associated Cognitive Deficits
Intepirdine for Dementia with Lewy Bodies
Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's Disease
Classification and Signaling Characteristics of 5-HT Receptors
1 Npharm Spec S6d3 Text Resub 010420
Autophagy in Neurodegeneration
Statistical Analysis Plan for Protocol RVT-101-3001 Version: August 9, 2017
Change in Expression of 5-HT6 Receptor at Different Stages of Alzheimer’S Disease: a Postmortem Study with the PET Radiopharmaceutical [ 18F ]2FNQ1P
Spotlight on Axovant After Lundbeck's Alzheimer's Failure
Dual 5-HT 6 and D 3 Receptor Antagonists in a Group Of
Alcohol Link to Dementia Is “Robust”
July 2017 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
Top View
Fragment-Based Approaches in GPCR-Targeted Drug Discovery Thesis
Prezentacja Programu Powerpoint
UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
Alzheimer's Disease
Alzheimer's Disease Drug Development Pipeline: 2018
Intepirdine for Alzheimer's Disease – Add on Therapy
Axovant to Present Patient Function and Independence Data Analyses from Phase 2B Study of Investigational Treatment Intepirdine in Alzheimer's Disease at CTAD 2016
Multi-Target Design Strategies for the Improved Treatment of Alzheimer's Disease
Optumrx Brand Pipeline Forecast
Shuffle Off to Buffalo PSSNY Tammie Lee Demler, BS., Pharm.D, MBA., BCGP
WO 2018/035157 Al 22 February 2018 (22.02.2018) W ! P O P C T
Phosphodiesterase Inhibitors Say NO to Alzheimer's Disease
5-HT Receptor Serotonin Receptor; 5-Hydroxytryptamine Receptor
Drug Repurposing Compound Library Plus (96-Well)
Neurological Disease
Suffixes Used in the Selection of INN and Their Published INN May 2018
Neuronal Signaling
Axovant Scraps Alzheimer's Bid – Now Back to the Amyloid Hypothesis